{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:06:03Z","timestamp":1781885163380,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"publisher","award":["1193796"],"award-info":[{"award-number":["1193796"]}],"id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024253","name":"Western Australian Future Health and Innovation Fund, Government of Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcf.2026.01.005","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T04:50:45Z","timestamp":1769143845000},"page":"544-550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Common inflammatory markers predict risk of ABPA development in children with cystic fibrosis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6591-1605","authenticated-orcid":false,"given":"Harriet E.D.","family":"Crabtree","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8865-090X","authenticated-orcid":false,"given":"Chris J.","family":"Malajczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Yin","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillipa M.","family":"Edmiston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6284-612X","authenticated-orcid":false,"given":"Daniel K.","family":"Yeoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya V.","family":"Karpievitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.01.005_bib0001","series-title":"Kendig and Wilmott\u2019s Disorders Of The Respiratory Tract In Children","first-page":"779","article-title":"Hypersensitivity pneumonitis and eosinophilic lung diseases","author":"Liptzin","year":"2023"},{"issue":"9","key":"10.1016\/j.jcf.2026.01.005_bib0002","article-title":"Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","volume":"9","author":"Francis","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcf.2026.01.005_bib0003","first-page":"35","article-title":"Question 11: how should allergic bronchopulmonary aspergillosis [ABPA] be managed in Cystic fibrosis?","volume":"24","author":"Ohn","year":"2017","journal-title":"Paediatr Respir Rev"},{"issue":"Suppl 3","key":"10.1016\/j.jcf.2026.01.005_bib0004","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1086\/376525","article-title":"Allergic bronchopulmonary aspergillosis in cystic fibrosis\u2013state of the art: cystic fibrosis foundation consensus conference","volume":"37","author":"Stevens","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.jcf.2026.01.005_bib0005","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.4187\/respcare.08531035","article-title":"Aspergillus\/allergic bronchopulmonary aspergillosis in an Irish cystic fibrosis population: a diagnostically challenging entity","volume":"53","author":"Chotirmall","year":"2008","journal-title":"Respir Care"},{"issue":"3","key":"10.1016\/j.jcf.2026.01.005_bib0006","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MOP.0000000000000898","article-title":"Manifestations of pulmonary aspergillosis in pediatrics","volume":"32","author":"Chacko","year":"2020","journal-title":"Curr Opin Pediatr"},{"issue":"11","key":"10.1016\/j.jcf.2026.01.005_bib0008","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrmicro.2017.90","article-title":"Aspergillus fumigatus morphology and dynamic host interactions","volume":"15","author":"van de Veerdonk","year":"2017","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"10.1016\/j.jcf.2026.01.005_bib0009","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1055\/s-0043-1776912","article-title":"Clinical manifestation and treatment of allergic bronchopulmonary aspergillosis","volume":"45","author":"Agarwal","year":"2024","journal-title":"Semin Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.jcf.2026.01.005_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/jof10090656","article-title":"Allergic bronchopulmonary aspergillosis (ABPA) in the era of Cystic Fibrosis transmembrane conductance regulator (CFTR) modulators","volume":"10","author":"Chatterjee","year":"2024","journal-title":"J Fungi"},{"issue":"8","key":"10.1016\/j.jcf.2026.01.005_bib0011","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","article-title":"Pathophysiology and management of pulmonary infections in cystic fibrosis","volume":"168","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2026.01.005_bib0012","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ccm.2021.12.002","article-title":"Allergic bronchopulmonary aspergillosis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Clin Chest Med"},{"issue":"9678","key":"10.1016\/j.jcf.2026.01.005_bib0013","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jcf.2026.01.005_bib0014","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00061-2024","article-title":"Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis\/mycoses","volume":"63","author":"Agarwal","year":"2024","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2026.01.005_bib0015","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.jaip.2017.03.033","article-title":"Increasing total serum IgE, allergic bronchopulmonary aspergillosis, and lung function in cystic fibrosis","volume":"5","author":"Gothe","year":"2017","journal-title":"J Allergy Clin Immunol Pr"},{"issue":"2","key":"10.1016\/j.jcf.2026.01.005_bib0016","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1128\/CMR.15.2.194-222.2002","article-title":"Lung infections associated with cystic fibrosis","volume":"15","author":"Lyczak","year":"2002","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"10.1016\/j.jcf.2026.01.005_bib0017","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jaip.2020.12.064","article-title":"Biomarkers for the diagnosis of allergic bronchopulmonary aspergillosis in Cystic Fibrosis: a systematic review and meta-analysis","volume":"9","author":"Li","year":"2021","journal-title":"J Allergy Clin Immunol Pr"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2026.01.005_bib0018","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.3109\/13693786.2010.514301","article-title":"Serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis: state of the art and further challenges","volume":"48","author":"Delhaes","year":"2010","journal-title":"Med Mycol"},{"issue":"1","key":"10.1016\/j.jcf.2026.01.005_bib0019","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.prrv.2009.01.001","article-title":"Diagnosing allergic bronchopulmonary aspergillosis in children with cystic fibrosis","volume":"10","author":"Thia","year":"2009","journal-title":"Paediatr Respir Rev"},{"issue":"2","key":"10.1016\/j.jcf.2026.01.005_bib0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/mmy\/myy014","article-title":"The diagnosis and management of respiratory tract fungal infection in cystic fibrosis: a UK survey of current practice","volume":"57","author":"Boyle","year":"2019","journal-title":"Med Mycol"},{"issue":"5","key":"10.1016\/j.jcf.2026.01.005_bib0021","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1164\/rccm.201810-1919OC","article-title":"Changing prevalence of lower airway infections in young children with Cystic fibrosis","volume":"200","author":"Breuer","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcf.2026.01.005_bib0022","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/cid\/cir399","article-title":"Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis","volume":"53","author":"Gangell","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.jcf.2026.01.005_bib0023","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/cea.12595","article-title":"Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis","volume":"45","author":"Maturu","year":"2015","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.jcf.2026.01.005_bib0024","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1164\/rccm.201908-1585OC","article-title":"Aspergillus infections and progression of structural lung disease in children with cystic fibrosis","volume":"201","author":"Breuer","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.01.005_bib0025","unstructured":"Cystic Fibrosis Foundation Patient Registry 2023 Annual Data Report Bethesda, Maryland: Cystic Fibrosis Foundation; 2024 [Available from: file:\/\/\/C:\/Users\/he157257\/Downloads\/2023-Patient-Registry-Annual-Data-Report.pdf."},{"issue":"11","key":"10.1016\/j.jcf.2026.01.005_bib0026","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/ppul.24465","article-title":"An investigation into biomarkers for the diagnosis of ABPA and aspergillus disease in cystic fibrosis","volume":"54","author":"Keown","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.01.005_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1180826","article-title":"Proliferative activity of antigen-specific CD154+ T cells against bacterial and fungal respiratory pathogens in cystic fibrosis decreases after initiation of highly effective CFTR modulator therapy","volume":"14","author":"Eschenhagen","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jcf.2026.01.005_bib0028","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13223-023-00822-2","article-title":"The impact of CFTR modulator triple therapy on type 2 inflammatory response in patients with cystic fibrosis","volume":"19","author":"Mehta","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"10.1016\/j.jcf.2026.01.005_bib0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","volume":"22","author":"Southern","year":"2023","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932600024X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932600024X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:45:12Z","timestamp":1781883912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932600024X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S156919932600024X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.01.005","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Common inflammatory markers predict risk of ABPA development in children with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}